View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 12, 2011

HyQ Found Effective for Primary Immunodeficiency

Baxter and Halozyme Therapeutics have released top-line results from a Phase III study of a HyQ, a subcutaneous immune globulin product to treat primary immunodeficiency. The prospective, open-label study, which enrolled 89 patients across 15 centres in the US and Canada, demonstrated

By cms admin

Baxter and Halozyme Therapeutics have released top-line results from a Phase III study of a HyQ, a subcutaneous immune globulin product to treat primary immunodeficiency.

The prospective, open-label study, which enrolled 89 patients across 15 centres in the US and Canada, demonstrated the efficacy and tolerability of HyQ in the prevention of infections.

The completion of the trial established a foundation for the HyQ extension study that will further evaluate administration of the drug.

Baxter is developing HyQ using a recombinant human hyaluronidase technology platform licensed from Halozyme Therapeutics.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology